Suda Pharmaceuticals Ltd represents a strong commitment to innovation, integrity, and providing advanced pharmaceutical solutions. The company values transparency, efficacy, and patient-centric healthcare. Suda Pharmaceuticals is dedicated to developing and commercializing novel products that address significant unmet medical needs. With a focus on enhancing patient outcomes and quality of life, Suda Pharmaceuticals prioritizes research and development to deliver safe and effective treatments. By leveraging cutting-edge technology and a customer-centric approach, the company aims to become a global leader in the pharmaceutical industry.

Suda Pharmaceuticals Ltd primarily operates in Australia, the United States, and China. With its headquarters based in Australia, Suda Pharmaceuticals has expanded its presence in key regions including the US and China. This pharmaceutical company specializes in developing and commercializing oral spray formulations for various therapies. Suda Pharmaceuticals has established partnerships and distribution networks in these countries to ensure effective market reach and maximize growth opportunities. With its focus on these prominent regions, Suda Pharmaceuticals aims to serve a wide range of patients and healthcare providers globally.

Suda Pharmaceuticals Ltd has achieved several significant milestones. The company successfully completed the clinical development of SUD-001, a spray formulation for the treatment of migraines, and received regulatory approval in Australia. Furthermore, Suda Pharmaceuticals established partnerships with reputable pharmaceutical companies to license and distribute their products globally. The company's innovative drug delivery technology enabled the development and commercialization of various therapeutic products, enhancing patient convenience and treatment outcomes. Additionally, Suda Pharmaceuticals expanded its presence in international markets and continues to actively explore new collaborations and growth opportunities.

Suda Pharmaceuticals Ltd is an Australian-based pharmaceutical company with a rich history and background. Established in 2002, the company focuses on developing and commercializing innovative pharmaceuticals for various therapeutic areas. Suda Pharmaceuticals has carved a niche in the industry by utilizing its patented OroMist® technology, which enables drugs to be delivered orally via oral sprays or films. This pioneering approach has proved beneficial in enhancing drug absorption, increasing patient compliance, and addressing various medical conditions. Suda Pharmaceuticals has dedicated significant efforts to advancing its product pipeline and establishing strategic partnerships with global pharmaceutical companies. With a commitment to improving patient outcomes and a strong foundation in drug delivery technology, Suda Pharmaceuticals continues to make strides in the pharmaceutical industry.

Some of the main competitors of Suda Pharmaceuticals Ltd in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, and GlaxoSmithKline.

Suda Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

The business model of Suda Pharmaceuticals Ltd revolves around developing and commercializing pharmaceutical products utilizing its OroMist® technology. The company focuses on designing, formulating, and delivering medicine through the oral mucosa, providing a non-invasive and convenient alternative to traditional oral pills or injections. Suda Pharmaceuticals Ltd aims to enhance the efficacy, safety, and patient compliance of existing drugs by utilizing its patented spray technology. By leveraging this innovative approach, Suda Pharmaceuticals Ltd aims to carve a niche in the pharmaceutical industry, meeting the growing demand for more efficient and patient-friendly drug delivery options.

Suda Pharmaceuticals P/E-luku on −1,82.

Suda Pharmaceuticals KUV on 7,29.

AlleAktien Laatuscore Suda Pharmaceuticals on 5/10.

odotettu Suda Pharmaceuticals liikevaihto on 2,04 milj. AUD.

odotettu Suda Pharmaceuticals voitto on −8,17 milj. AUD.

Suda Pharmaceuticals Ltd is an Australian biopharmaceutical company specializing in the development of oral sprays for the treatment of diseases and ailments. The company was founded in 2000 and is headquartered in Perth, Australia. Suda is listed on the Australian stock exchange and trades under the ticker symbol "SUD". The company operates in two main business segments: Pharma and Nutra. In the Pharma segment, the company focuses on the development of oral sprays for the treatment of pain, nausea, epilepsy, and other diseases. Suda has already successfully launched a number of sprays on the market, such as ZolpiMist for the treatment of insomnia and SUD-003 for the treatment of migraines. In the Nutra segment, the company focuses on dietary supplements and functional foods. The goal is to bring products to market that can improve consumers' health and well-being. Suda combines traditional medical knowledge with modern scientific findings to achieve this. Suda's business model is designed to generate revenue by developing innovative products and marketing them globally. The company invests significant amounts in research and development and has a team of highly qualified experts and scientists who collaborate closely with leading academic institutions and research facilities. Suda also has a strong pipeline of products in development that have the potential to provide long-term stability for the company. An example of this is the spray anesthesia Anagrelide, which has already shown promising results in clinical trials. To successfully pursue its business model, Suda works closely with partners to market its products worldwide. The company has already entered into a number of distribution partnerships with reputable pharmaceutical companies and distributors to bring its products to market in various countries. Suda also has a strong presence in Asia, particularly in Japan. The company has developed an extensive strategy in the Asian region to sell its products. This increases the availability of its products in this region, which in turn has the potential to generate significant revenue. In summary, Suda Pharmaceuticals Ltd is a biopharmaceutical company specializing in the development of oral sprays for the treatment of diseases and ailments. The company operates in two main business segments: Pharma and Nutra. Suda's business model focuses on the development of innovative products and their global marketing. The company has a strong pipeline of products in development and works closely with partners to distribute its products worldwide.

Suda Pharmaceuticals maksaa osinkoa 0 AUD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Suda Pharmaceuticals:lle tai yhtiö ei maksa osinkoa.

Suda Pharmaceuticals:n ISIN on AU000000SUD7.

Suda Pharmaceuticals:n WKN on A1J9SF.

Suda Pharmaceuticals:n tunnus on SUD.AX.

Viimeisen 12 kuukauden aikana Suda Pharmaceuticals maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Suda Pharmaceuticals maksanee ennusteiden mukaan 0 AUD osingon.

Suda Pharmaceuticals:n tämänhetkinen osinkotuotto on .

Suda Pharmaceuticals maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Suda Pharmaceuticals maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 AUD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Suda Pharmaceuticals kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Suda Pharmaceuticals osingon 16.9.2024, jonka suuruus on 0 AUD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 16.9.2024.

Viimeisin osinko maksettiin 16.9.2024.

Vuonna 2023 Suda Pharmaceuticals maksoi 0 AUD osinkoina.

Suda Pharmaceuticals:n osingot maksetaan AUDssa.